Chinese Clinical Oncology is a distinguished journal dedicated to advancing the field of oncology and clinical research, published by AME Publishing Company. Since its inception in 2012, this journal has established its significance within the academic community, boasting an impactful presence as evidenced by its 2023 Scopus rankings, where it is positioned in the 47th percentile in the field of oncology. This open access journal features a diverse range of research, reviews, and clinical studies that aim to bridge the gap between experimental and clinical oncology, making it an invaluable resource for researchers, medical professionals, and students alike. The journal is based in Hong Kong and is committed to publishing studies that contribute to the understanding and treatment of cancer, with a strong focus on innovative methodologies and emerging therapies. With a current categorization of Q2 in Medicine and Q3 in Oncology, Chinese Clinical Oncology offers a robust platform for scholarly communication and is pivotal for those involved in cancer research and treatment.

Kidney Cancer, published by IOS PRESS, is an esteemed open-access journal dedicated to advancing knowledge in the field of nephrology and oncology. Since its inception in 2017, this journal has provided a dynamic platform for researchers, practitioners, and students to disseminate their findings and discuss innovative approaches to kidney cancer treatment and research. With an ongoing commitment to fostering collaboration and sharing critical insights, Kidney Cancer aims to bridge gaps in understanding and promote new methodologies in patient care. Despite its current ranking in the lower quartiles of its category, the journal is positioned to make significant contributions to the academic community by publishing high-quality, peer-reviewed articles that enhance the discourse in kidney cancer research. Furthermore, its open-access model ensures that valuable research is accessible to a global audience, supporting the urgent need for advancements in this critical area of health. Join the conversation and contribute to the growing body of knowledge in this vital field.

Hematology Reports is an esteemed academic journal in the field of hematology, dedicated to advancing the understanding of blood disorders and their treatment. Published by MDPI, a leading Swiss publisher known for its commitment to open access since 2009, this journal provides a valuable platform for researchers and healthcare professionals to disseminate innovative findings and foster collaboration within the academic community. The journal features an array of articles ranging from clinical studies to laboratory research, and is indexed in Scopus, where it currently holds a rank of 113 out of 137 in the Medicine - Hematology category, placing it in the 17th percentile. As an open-access journal, Hematology Reports ensures that critical research is accessible to a global audience, supporting the dissemination of knowledge that has the potential to improve patient outcomes. This journal is an essential resource for those engaged in the study and treatment of hematological conditions, encouraging dialogue and the exchange of ideas to enhance clinical practices.

Nephrologie & Therapeutique is a distinguished peer-reviewed journal published by JOHN LIBBEY EUROTEXT LTD, dedicated to the field of nephrology. Since its inception in 2005, this journal has been pivotal in disseminating high-quality research in the areas of kidney disease, renal therapies, and nephrological advancements, and it continues to serve as an essential resource for professionals, researchers, and students alike. With an ISSN of 1769-7255 and an E-ISSN of 1872-9177, the journal is indexed in Scopus and is currently ranked in the third quartile (Q3) within the nephrology category, showing significant contributions to the discipline, despite its current ranking of 64 out of 81. Although Nephrologie & Therapeutique does not operate under an open access model, it nevertheless provides valuable insights and updates on the latest findings and practices in nephrology, making it an important platform for academic discourse in this field. The journal's commitment to advancing knowledge and fostering interdisciplinary dialogue underscores its role as a key player in shaping future research and clinical practices in nephrology.

Case Reports in Oncological Medicine is a distinguished open-access journal published by HINDAWI LTD, dedicated to disseminating valuable insights and findings in the field of oncology. Since its inception in 2011, this journal has aimed to provide a unique platform for the publication of detailed case reports that contribute to our understanding of cancer diagnosis, treatment, and management. With a specific focus on sharing clinical experiences and outcomes, it seeks to engage researchers, healthcare professionals, and students who are committed to advancing oncological knowledge and improving patient care. Although coverage in Scopus was discontinued from 2014 to 2017, the journal currently holds a rank of #232/323 in Medicine - Oncology, placing it within the 28th percentile. Researchers interested in making their work accessible can benefit from the journal's open-access model, allowing greater visibility and citation potential within the scientific community. The journal is positioned as an important resource for those looking to stay updated on the latest case studies and innovations in oncological medicine.

Kidney & Blood Pressure Research, published by KARGER, is a premier open-access journal dedicated to the evolving fields of nephrology and cardiovascular medicine. Since its inception in 1978 and with a forward-looking scope extending to 2024, this journal plays a vital role in disseminating innovative research and clinical findings related to kidney health and blood pressure regulation. With an impressive 2023 Impact Factor and ranked in the second quartile (Q2) in both cardiology and nephrology categories, it is recognized as a significant resource among its peers, including a Scopus rank of #23 in Nephrology and #128 in Cardiology. The journal's commitment to open access since 2013 further ensures that cutting-edge research is readily available to the global scientific community. Based in Switzerland, the journal not only fosters academic collaboration but also addresses critical health challenges related to kidney function and hypertension. It is a crucial platform for researchers, healthcare professionals, and students alike, encouraging the ongoing dialogue and advancement of knowledge in these critical areas of health.

Renal Replacement Therapy is an esteemed open-access journal published by BMC, dedicated to advancing the field of nephrology, transplantation, and urology. Established in 2015, the journal aims to disseminate high-quality research findings to enhance the understanding and management of kidney-related diseases and therapies. Renal Replacement Therapy is ranked in the third quartile (Q3) in the categories of Nephrology, Transplantation, and Urology as of 2023, reflecting its growing influence and commitment to academic excellence. The journal encourages interdisciplinary study and collaboration, welcoming contributions from researchers, clinicians, and healthcare professionals. With a focus on practical applications and innovative therapies, this journal is instrumental for those seeking the latest insights and advancements in renal replacement strategies. Located in the United Kingdom, the journal strives to provide unparalleled access to critical research, ensuring that its findings are available to a global audience striving to improve patient outcomes in renal health.

BJU International is a prestigious academic journal specializing in the field of Urology, published by WILEY, one of the leading publishers in scientific literature. With an impressive impact factor and recognized as a Q1 journal in Urology for 2023, it ranks #7 out of 120 in the Scopus Medicine _ Urology category, placing it in the 94th percentile among its peers. Established in 1929 and with converged years from 1994 to 2024, BJU International provides a platform for groundbreaking research, clinical studies, and advancements in urological science. The journal is accessible in both print and online formats, catering to a global audience dedicated to enhancing urological practice and research. By fostering interdisciplinary dialogue and disseminating high-quality studies, BJU International plays a crucial role in advancing knowledge and improving patient care in the field of urology.

Renal Society of Australasia Journal, published by the Renal Society of Australasia, serves as a crucial platform for disseminating cutting-edge research and insights within the fields of nephrology and urology. With its ISSN of 1832-3804, this journal has been continually published since 2011, showcasing the evolving landscape of renal health in Australia and beyond. Despite currently holding a Q4 ranking in both nephrology and urology categories, the journal is committed to supporting the scientific community with rigorous peer-reviewed articles that enhance clinical practice and foster research advancement. As an open access journal, it aims to provide wide visibility and access to researchers, professionals, and students alike, thus promoting knowledge sharing among various stakeholders in renal health. Positioned within a global context, it addresses local health challenges while contributing to the broader discourse in renal sciences, making it an essential resource for those dedicated to improving patient outcomes in this critical area of medicine.

Kidney Diseases is an esteemed open-access journal published by KARGER that has been at the forefront of nephrology research since its inception in 2015. With an impressive Scopus ranking of #13 out of 81 in the field of Medicine Nephrology, placing it in the top 84th percentile, the journal has established itself as a vital resource for researchers, clinicians, and students interested in advancing knowledge on kidney health, disorders, and innovative treatment strategies. This journal aims to disseminate cutting-edge findings and clinical insights over a converged publication span from 2019 to 2024, fostering global collaboration and dialogue within the scientific community. With its commitment to open access, Kidney Diseases ensures that critical research is freely accessible, promoting wider dissemination of knowledge and the development of effective therapeutic interventions.